Startup · $2.3m raised
Biotech company developing VISTA targeting checkpoint inhibitor HMBD-002
Melbourne, VIC
Every investor coverage indicates participated in a round Percheron Therapeutics raised.
Companies Percheron Therapeutics acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Dr Michael Baker | Director | Biotech Dispatch |
| Dr Michael Baker | Chief Executive Officer and Managing Director | Biotech Dispatch |
| Dr James Garner | Chief Executive Officer and Managing Director | Biotech Dispatch, Wholesale Investor |
| Dr Charmaine Gittleson | Chair | Biotech Dispatch (1 Sep 2026), Biotech Dispatch (10 Aug 2026) |
Stories naming Percheron Therapeutics. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Melbourne biotech Percheron Therapeutics has locked in $2.3 million through an institutional placement to fund a Vanderbilt Health trial of its HMBD-002 antibody in blood cancers.
Wholesale Investor's news listing spanning Australian private capital: deep-tech and biotech company profiles, property and crypto commentary, Q1 2026 venture funding totals, and guides to wholesale investor qualification.
Percheron Therapeutics has appointed Arovella Therapeutics' former leader Michael Baker as CEO from October, with James Garner departing for an overseas role while joining the board as a non-executive director.
Profile of Percheron Therapeutics, an ASX-listed biotech led by Dr James Garner, developing HMBD-002 against the VISTA protein to treat cancers that resist PD-1 immunotherapy, with Phase 2 trials planned for 2026.